FindTrial
Sign In

Impact of immune check point inhibitors on airway function test and airway inflammations

Impact of immune check point inhibitors on airway function test and airway inflammations - Impact of immune check point inhibitors on airway function test and airway inflammations

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000021548
Enrollment
200
Registered
2016-03-30
Start date
2016-03-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer patients treated with immune checkpoint inhibitors

Interventions

None listed

Sponsors

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
Lead Sponsor
Seireimikatahara General Hospital Seirei Hamamatsu Hospital Tenryu Hospital Hamamatsu Medical Center Enshu Hospital Hamamatsu Rosai Hospital Iwata City Hospital Fujieda City Hospital Shizuoka Ciy Shizuoka Hospital Hamamatsu Red-cross Hospital Shizuoka Red-cross Hospital Shizuoka Saiseikai Hospital Shizuoka City Shimizu Hospital Shizuoka General Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Cancer patients who are treated with immune checkpoint inhibitors

Exclusion criteria

Exclusion criteria: Patients not obtained written informed consents

Design outcomes

Primary

MeasureTime frame
Pulmonary function, Exhaled NO, inflammatory markers in 8 weeks after treatments—

Secondary

MeasureTime frame
Exacerbation of airway inflammations—

Countries

Japan

Contacts

Public ContactYuzo Suzuki

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

yuzosuzu@hama-med.ac.jp053-435-2263

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026